Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial


Athenex Inc's ATNX abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium.

  • The abstract and poster provide data from a post hoc, subgroup analysis of safety, progression-free survival, and overall survival of patients with elevated liver enzymes.
  • The trial is evaluating weekly oral Paclitaxel plus Encequidar vs. IV Paclitaxel 175mg/m2 every three weeks. 
  • Before treatment, 122 out of 402 total study patients (30.3%) had elevated AST or bilirubin, primarily mild hepatic dysfunction. 
  • The median survival of patients with elevated liver enzymes receiving Oral Paclitaxel was 18.9 months compared to 10.1 months for patients receiving IV Paclitaxel.
  • This increase in overall survival counterbalanced the risk of complications of neutropenia-related toxicities.
  • Price Action: ATNX shares are down 8.12% at $1.755 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralbreast cancerBriefsPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!